Sunday, November 1, 2026

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

January 7, 2021

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Brown & Brown, Inc.

6.3% sales growth and 13.1% return on equity

Brown & Brown, Inc. markets and sells insurance products and services in the United States, England, Canada, Bermuda, and the Cayman Islands.

Brown & Brown, Inc.'s sales growth this year is expected to be 8.5% and 7.1% for next year.

Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 2.54B for the twelve trailing months.

Brown & Brown, Inc.'s sales growth for the next quarter is 6.3%. The company's growth estimates for the present quarter and the next is 3.6% and 3.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.1%.

Volatility

Brown & Brown, Inc.'s last day, last week, and last month's average volatility was a negative 0.94%, a negative 0.04%, and a positive 0.00%, respectively.

Brown & Brown, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 2.03%, 1.62%, and 1.85%, respectively.

Brown & Brown, Inc.'s Stock Yearly Top and Bottom Value

Brown & Brown, Inc.'s stock is valued at $45.88 at 13:22 EST, under its 52-week high of $48.69 and way above its 52-week low of $30.70.

Brown & Brown, Inc.'s Moving Average

Brown & Brown, Inc.'s worth is under its 50-day moving average of $46.03 and above its 200-day moving average of $44.88.

Previous days news about Brown & Brown, Inc.

According to Business Insider on Monday, 4 January, "Insurance brokerage firm Brown & Brown, Inc. (BRO) announced Monday that it has acquired substantially all of the assets of Berry Insurance Group through its subsidiary Brown & Brown of Ohio, LLC. "

2. New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share

24.9% sales growth and 10.41% return on equity

New Oriental Education & Technology Group Inc. provides private educational services under the New Oriental brand in the People's Republic of China.

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's sales growth this year is expected to be 17.2% and 32.8% for next year.

Year-on-year quarterly revenue growth declined by 8%, now sitting on 3.49B for the twelve trailing months.

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's sales growth is a negative 0% for the current quarter and 24.9% for the next. The company's growth estimates for the present quarter and the next is 2.8% and 25.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.41%.

Volatility

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's last day, last week, and last month's average volatility was a negative 0.57%, a positive 0.07%, and a positive 0.08%, respectively.

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's last day, last week, and last month's high and low average amplitude percentage was 2.34%, 2.12%, and 2.72%, respectively.

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's Stock Yearly Top and Bottom Value

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's stock is valued at $167.09 at 13:22 EST, below its 52-week high of $184.60 and way above its 52-week low of $102.01.

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's Moving Average

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 1 Ordinary Share's value is below its 50-day moving average of $168.78 and above its 200-day moving average of $153.53.

3. AeroVironment, Inc.

7.3% sales growth and 5.69% return on equity

AeroVironment, Inc. designs, develops, produces, supports, and operates a portfolio of products and services for government agencies and businesses.

AeroVironment, Inc.'s sales growth this year is expected to be 9.8% and 8.6% for next year.

Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 377.23M for the twelve trailing months.

AeroVironment, Inc.'s sales growth is a negative 0% for the ongoing quarter and 7.3% for the next. The company's growth estimates for the present quarter and the next is 1000% and 16%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.69%.

Volatility

AeroVironment, Inc.'s last day, last week, and last month's average volatility was a negative 1.31%, a negative 0.70%, and a negative 0.02%, respectively.

AeroVironment, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 2.95%, 2.77%, and 3.79%, respectively.

AeroVironment, Inc.'s Stock Yearly Top and Bottom Value

AeroVironment, Inc.'s stock is valued at $86.90 at 13:22 EST, way below its 52-week high of $99.81 and way higher than its 52-week low of $45.00.

AeroVironment, Inc.'s Moving Average

AeroVironment, Inc.'s worth is higher than its 50-day moving average of $86.08 and way higher than its 200-day moving average of $76.81.

4. Synopsys, Inc.

18% sales growth and 14.74% return on equity

Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits.

Synopsys, Inc.'s sales growth this year is anticipated to be 9.3% and 8.2% for next year.

Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 3.69B for the twelve trailing months.

Synopsys, Inc.'s sales growth is a negative 0% for the current quarter and 18% for the next. The company's growth estimates for the present quarter and the next is 45.5% and 25.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.74%.

Volatility

Synopsys, Inc.'s last day, last week, and last month's average volatility was 0.91%, 0.36%, and 0.58%, respectively.

Synopsys, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 1.18%, 1.77%, and 2.46%, respectively.

Synopsys, Inc.'s Stock Yearly Top and Bottom Value

Synopsys, Inc.'s stock is valued at $259.24 at 13:22 EST, below its 52-week high of $261.13 and way higher than its 52-week low of $104.90.

Synopsys, Inc.'s Moving Average

Synopsys, Inc.'s value is above its 50-day moving average of $237.00 and way above its 200-day moving average of $214.96.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com